Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?

Sorry, there's nothing here.

Cite this paper

@article{Shepherd1998ShouldSE, title={Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?}, author={James Shepherd and Anders Olsson and Frank M . Sacks and Donald M Black and David G. Orloff and David W Bilheimer}, journal={The American journal of cardiology}, year={1998}, volume={81 8A}, pages={88F-94F} }